Department of Infectious Diseases and Clinical Microbiology, Bilecik Training and Research Hospital, Bilecik, Turkey.
Department of Infectious Diseases and Clinical Microbiology, Haseki Training and Research Hospital, Istanbul, Turkey.
Rev Med Chil. 2023 Oct;151(10):1319-1331. doi: 10.4067/s0034-98872023001001319.
The effect of COVID-19 on the outcomes of patients with Staphylococcus aureus bacteremia is still unknown.
In this study, we aimed to determine associated factors for mortality in patients with S. aureus bacteremia and to explore the impact of prior COVID-19.
In this retrospective and single-center study, all adult patients (≥ 18 years old) with S. aureus bacteremia between March 2020 and February 2022 were included.
The outcomes of our study were 14-day and 28-day hospital mortality after the first positive blood culture was obtained. Univariate and Cox regression analyses were performed.
A total of 140 patients with S. aureus bacteremia were included in the study. The median age was 64.5 (48.5-76) and 82 (58.5%) of the patients were male. 14-day and 28-day mortality rates were 28.6% and 37.1% respectively. Among patients with S. aureus bacteremia and previous COVID-19 history, 14-day and 28-day mortality rates were 33.9% (n = 21) and 41.9% (n = 26), respectively. Cox regression analysis revealed that Pitt bacteremia score, AST, urea, and previous antibiotic use were associated factors for 14-day mortality and 28-day mortality due to S. aureus bacteremia.
This study justified the remarkable fatality of S. aureus bacteremia during the COVID-19 pandemic period and revealed that a high Pitt bacteremia score, increased levels of AST and urea, and previous antibiotic exposure were associated factors for mortality in patients with S. aureus bacteremia.
本研究旨在确定金黄色葡萄球菌菌血症患者死亡的相关因素，并探讨既往 COVID-19 的影响。
在这项回顾性和单中心研究中，纳入了 2020 年 3 月至 2022 年 2 月期间所有金黄色葡萄球菌菌血症的成年患者（≥18 岁）。
本研究的结局为首次阳性血培养后 14 天和 28 天的院内死亡率。进行了单因素和 Cox 回归分析。
共纳入 140 例金黄色葡萄球菌菌血症患者。中位年龄为 64.5（48.5-76）岁，82 例（58.5%）为男性。14 天和 28 天的死亡率分别为 28.6%和 37.1%。在有金黄色葡萄球菌菌血症和既往 COVID-19 病史的患者中，14 天和 28 天的死亡率分别为 33.9%（n=21）和 41.9%（n=26）。Cox 回归分析显示，Pitt 菌血症评分、AST、尿素和既往抗生素使用是金黄色葡萄球菌菌血症 14 天和 28 天死亡率的相关因素。
本研究证实了 COVID-19 大流行期间金黄色葡萄球菌菌血症的显著病死率，并揭示了高 Pitt 菌血症评分、AST 和尿素水平升高以及既往抗生素暴露是金黄色葡萄球菌菌血症患者死亡的相关因素。
